Centiva Capital’s Axsome Therapeutics AXSM Stock Holding History

Centiva Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,500	Closed	-$225K	–	1687
2024 Q3	$225K	Buy	+2,500	New	+$218K	﹤0.01%	1758

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Centiva Capital's AXSM Position: Q2 2026 in Review

Centiva Capital sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 1,288 shares — an estimated $218K sold.

Centiva Capital first reported a position in AXSM in Q2 2020 and held it in 3 quarters. The position peaked at $424K in Q2 2020. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Centiva Capital reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 1,288 Axsome Therapeutics shares in Q2 2026, an estimated $218K.
Centiva Capital first reported a position in Axsome Therapeutics in Q2 2020 and held it in 3 quarters.
Centiva Capital's Axsome Therapeutics position peaked at $424K in Q2 2020.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.